PRA Health Sciences (NASDAQ:PRAH) released its quarterly earnings results on Wednesday. The medical research company reported $1.22 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.11 by $0.11, Briefing.com reports. The firm had revenue of $763.31 million during the quarter, compared to analysts’ expectations of $764.95 million. PRA Health Sciences had a return on equity of 26.87% and a net margin of 5.50%. PRA Health Sciences’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.00 EPS. PRA Health Sciences updated its FY 2019 guidance to $4.98-5.08 EPS.
Shares of PRAH stock traded up $3.26 on Friday, hitting $96.76. 1,588,823 shares of the stock traded hands, compared to its average volume of 548,671. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 1.12. The company has a market cap of $6.14 billion, a P/E ratio of 24.62, a PEG ratio of 1.40 and a beta of 1.12. PRA Health Sciences has a 1-year low of $82.12 and a 1-year high of $121.98. The stock’s fifty day moving average is $98.53.
A number of equities analysts have weighed in on PRAH shares. Leerink Swann started coverage on PRA Health Sciences in a report on Tuesday, July 2nd. They issued a “market perform” rating and a $105.00 price target for the company. ValuEngine cut PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, April 13th. BidaskClub upgraded PRA Health Sciences from a “hold” rating to a “buy” rating in a research note on Wednesday, July 24th. Mizuho set a $100.00 target price on PRA Health Sciences and gave the company a “hold” rating in a research note on Friday, May 3rd. Finally, Svb Leerink reiterated a “market perform” rating on shares of PRA Health Sciences in a research note on Tuesday, July 2nd. Eight investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $113.00.
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Further Reading: Elliott Wave Theory
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.